What Held Pfizer (NYSE:PFE) Back 2.2% Even After a Guidance Lift?

Vinay Lochav

05 November 2026 12:49 AM AEDT

What Held Pfizer (NYSE:PFE) Back 2.2% Even After a Guidance Lift?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Pfizer (NYSE:PFE) slipped about 2.2% on November 3, 2026, after adjusted Earnings of USD 0.87 a share topped a published estimate of USD 0.73.
Revenue guidance for 2026 rose to USD 62.0 billion to USD 64.0 billion from USD 60.5 billion to USD 62.5 billion, with adjusted earnings guided to USD 2.95 to USD 3.05.
Third-quarter Revenue of USD 16,583 million was nearly flat against USD 16,654 million a year earlier, and adjusted EPS was unchanged at USD 0.87.
Operational growth reached 7% once Comirnaty and Paxlovid were excluded, while launched and acquired products rose 32%, and Paxlovid alone fell USD 771 million, or 63%.

What Pfizer Reported

Pfizer released third-quarter 2026 results on November 3, 2026. Revenue came to USD 16,583 million, against USD 16,654 million a year earlier. Reported diluted earnings were USD 0.56, down from USD 0.62, while adjusted diluted earnings held at USD 0.87. The company lifted its 2026 revenue guidance to USD 62.0 billion to USD 64.0 billion and narrowed adjusted earnings guidance to USD 2.95 to USD 3.05 from USD 2.80 to USD 3.00. The shares closed about 2.2% lower, according to published market data. Over nine months revenue reached USD 46,067 million, up 2%, and adjusted earnings totalled USD 2.39 a share against USD 2.56. The full-year range therefore points to fourth-quarter adjusted earnings of roughly USD 0.56 to USD 0.66, simple arithmetic.

Where Growth Came From and Where It Fell Away

Newer and established medicines carried the quarter. Eliquis added USD 513 million, or 25%, Padcev added USD 255 million, or 55%, Vyndaqel added USD 193 million, or 12%, Nurtec added USD 135 million, or 33%, and Lorbrena added USD 114 million, or 43%. The drags were Paxlovid, down USD 771 million or 63%, Comirnaty, down USD 339 million or 29%, and the Prevnar family, down USD 180 million or 10%. Strip out the two COVID products and revenue grew 7% on an operational basis. The earnings guide also absorbs a one-time USD 650 million acquired research charge tied to the Innovent Biologics agreement, worth about USD 0.10 a share.

Risks and What to Watch Next

The steepest headwind is the decline in COVID revenue, which still takes more than a billion dollars a quarter out of reported growth. Restructuring is costly, with charges of USD 742 million in the quarter and USD 1,167 million over nine months as part of a company-wide cost overhaul. Reported earnings fell while adjusted earnings were flat, which keeps Quality of Earnings in focus. The beat against USD 0.73 failed to lift the stock, suggesting investors wanted faster growth. Eliquis alone contributed a gain larger than any other single product change. Pfizer (NYSE:PFE) will need to show progress on its pipeline, cost savings and a faster pace of non-COVID growth. The midpoint of revenue guidance rose by USD 1.5 billion, a clear sign of confidence, yet the earnings range now carries a charge that makes the year-on-year comparison harder.

Where Things Stand

Pfizer edged down about 2.2% because investors had hoped for more than a flat quarter, even though adjusted EPS of USD 0.87 beat expectations and revenue guidance was raised. Newer products are expanding while COVID sales shrink quickly and restructuring costs remain high. For Pfizer (NYSE:PFE), non-COVID growth and savings from the cost programme are the figures to track. The dip may reflect expectations more than the numbers themselves, and it was small next to some moves elsewhere that day. Nothing here is Investment advice.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.